Current status of toxoplasmosis vaccine development
| Autor: | Lucyna Holec-Gasior, Józef Kur, Elżbieta Hiszczyńska-Sawicka |
|---|---|
| Rok vydání: | 2009 |
| Předmět: |
Protozoan Vaccines
Biomedical Research medicine.medical_treatment Immunology Disease Abortion DNA vaccination Immune system parasitic diseases Drug Discovery medicine Animals Humans Pharmacology biology Toxoplasma gondii medicine.disease biology.organism_classification Virology Toxoplasmosis Molecular Medicine Congenital disease Adjuvant Toxoplasma |
| Zdroj: | Expert review of vaccines. 8(6) |
| ISSN: | 1744-8395 |
| Popis: | Toxoplasmosis, caused by an intracellular protozoan parasite, Toxoplasma gondii, is widespread throughout the world. The disease is of major medical and veterinary importance, being a cause of congenital disease and abortion in humans and domestic animals. In addition, recently it has gained importance owing to toxoplasma encephalitis in AIDS patients. In the last few years, there has been considerable progress towards the development of a vaccine for toxoplasmosis, and a vaccine based on the live-attenuated S48 strain was developed for veterinary uses. However, this vaccine is expensive, causes side effects and has a short shelf life. Furthermore, this vaccine may revert to a pathogenic strain and, therefore, is not suitable for human use. Various experimental studies have shown that it may be possible to develop a vaccine against human toxoplasmosis. Recent progress in knowledge of the protective immune response generated by T. gondii and the current status of development of a vaccine for toxoplasmosis are highlighted. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|